Behshad Pournasr

Behshad Pournasr

Auto-generated profile, based on publicly available information

Behshad Pournasr

Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2010 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
AGArefeh Ghodsizadeh
Arefeh Ghodsizadeh
ATAdeleh Taei
Adeleh Taei
MTMehdi Totonchi
Mehdi Totonchi
ASAli Seifinejad
Ali Seifinejad
HGHamid Gourabi
Hamid Gourabi
HBHossein Baharvand
Hossein Baharvand

1 March 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MSMona Saheli
Mona Saheli
MSMohammadmajid Sepantafar
Mohammadmajid Sepantafar
BPBehshad Pournasr
Behshad Pournasr
ZFZahra Farzaneh
Zahra Farzaneh
Massoud VosoughMassoud Vosough
Massoud Vosough
HBHossein Baharvand
Hossein Baharvand

3 June 2013 in Stem Cells and Development
Verified
Journal Article
Closed access
Massoud VosoughMassoud Vosough
Massoud Vosough
EOEskandar Omidinia
Eskandar Omidinia
MKMehdi Kadivar
Mehdi Kadivar
MSMohammad ali Shokrgozar
Mohammad ali Shokrgozar
BPBehshad Pournasr
Behshad Pournasr
HBHossein Baharvand
Hossein Baharvand
Recent advances in human embryonic and induced pluripotent stem cell-based therapies in animal models of hepatic failure have led to an increased appreciation of the need to translate the proof-of-principle concepts into more practical and feasible protocols for scale up and manufacturing of functional hepatocytes. In this study, we describe a scalable stirred-suspension bioreactor culture of functional hepatocyte-like cells (HLCs) from the human pluripotent stem cells (hPSCs). To promote the initial differentiation of hPSCs in a carrier-free suspension stirred bioreactor into definitive endoderm, we used rapamycin for “priming” phase and activin A for induction. The cells were further differentiated into HLCs in the same system. HLCs were characterized and then purified based on their physiological function, the uptake of DiI-acetylated low-density lipoprotein (LDL) by flow cytometry without genetic manipulation or antibody labeling. The sorted cells were transplanted into the spleens of mice with acute liver injury from carbon tetrachloride. The differentiated HLCs had multiple features of primary hepatocytes, for example, the expression patterns of liver-specific marker genes, albumin secretion, urea production, collagen synthesis, indocyanin green and LDL uptake, glycogen storage, and inducible cytochrome P450 activity. They increased the survival rate, engrafted successfully into the liver, and continued to present hepatic function (i.e., albumin secretion after implantation). This amenable scaling up and outlined enrichment strategy provides a new platform for generating functional HLCs. This integrated approach may facilitate biomedical applications of the hPSC-derived hepatocytes.

11 November 2011 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
SASamira Asgari
Samira Asgari
MMMohsen Moslem
Mohsen Moslem
KLKamran Bagheri Lankarani
Kamran Bagheri Lankarani
BPBehshad Pournasr
Behshad Pournasr
MMMaryam Miryounesi
Maryam Miryounesi
HBHossein Baharvand
Hossein Baharvand

15 December 2016 in Stem Cells and Development
Verified
Journal Article
Closed access
MLMajid Lotfinia
Majid Lotfinia
MKMehdi Kadivar
Mehdi Kadivar
Abbas PiryaeiAbbas Piryaei
Abbas Piryaei
BPBehshad Pournasr
Behshad Pournasr
SSSoroush Sardari
Soroush Sardari
HBHossein Baharvand
Hossein Baharvand
Adult tissue-derived mesenchymal stem cells (MSCs) show tremendous promise for a wide array of therapeutic applications predominantly through paracrine activity. Recent reports showed that human embryonic stem cell (ESC)-derived MSCs are an alternative for regenerative cellular therapy due to manufacturing large quantities of MSCs from a single donor. However, no study has been reported to uncover the secretome of human ESC-MSCs as treatment of an acute liver failure (ALF) mouse model. We demonstrated that human ESC-MSCs showed similar morphology and cell surface markers compared with bone marrow-derived MSCs. ESC-MSCs exhibited a higher growth rate during early in vitro expansion, along with adipogenic and osteogenic differentiation potential. Treatment with ESC-MSC-conditioned medium (CM) led to statistically significant enhancement of primary hepatocyte viability and increased immunomodulatory interleukin-10 secretion from lipopolysaccharide-induced human blood mononuclear cells. Analysis of the MSCs secretome by a protein array screen showed an association between higher frequencies of secretory proteins such as vascular endothelial growth factor (VEGF) and regulation of cell proliferation, cell migration, the development process, immune system process, and apoptosis. In this thioacetamide-induced mouse model of acute liver injury, we observed that systemic infusion of VEGF led to significant survival. These data have provided the first experimental evidence of the therapeutic potential of human ESC-MSC-derived molecules. These molecules show trophic support to hepatocytes, which potentially creates new avenues for the treatment of ALF, as an inflammatory condition.

1 October 2010 in Journal of Hepatology
Verified
Journal Article
Open access
SASamira Asgari
Samira Asgari
BPBehshad Pournasr
Behshad Pournasr
GSGhasem Hosseini Salekdeh
Ghasem Hosseini Salekdeh
AGArefeh Ghodsizadeh
Arefeh Ghodsizadeh
MOMichael Ott
Michael Ott
HBHossein Baharvand
Hossein Baharvand
Stem cell transplantation has been proposed as an attractive alternative approach to restore liver mass and function. Recent progress has been reported on the generation of induced pluripotent stem (iPS) cells from somatic cells. Human-iPS cells can be differentiated towards the hepatic lineage which presents possibilities for improving research on diseases, drug development, tissue engineering, the development of bio-artificial livers, and a foundation for producing autologous cell therapies that would avoid immune rejection and enable correction of gene defects prior to cell transplantation. This focused review will discuss how human iPS cell advances are likely to have an impact on hepatology.